Division of Rheumatology, Department of Internal Medicine, University of Palermo, Piazza delle Cliniche 2, 90127, Palermo, Italy.
Rheumatol Int. 2010 Sep;30(11):1437-40. doi: 10.1007/s00296-009-1157-3. Epub 2009 Oct 23.
The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated.
相当数量的强直性脊柱炎（AS）患者的体征和症状对非甾体抗炎药、皮质类固醇和改善病情抗风湿药反应不佳。肿瘤坏死因子抑制剂在临床试验中已被证明可降低 AS 的疾病活动度。在一项为期 2 年的开放性标签随机研究中比较了依那西普和英夫利昔单抗在强直性脊柱炎患者中的疗效和安全性。我们的结果与英夫利昔单抗治疗组更显著的快速临床改善一致。研究结束时，依那西普和英夫利昔单抗的治疗均有效、安全且耐受良好。
